Open Innovation Research In Japan On iPS Cell-Derived Insulin Cells.
TOKYO, Japan, January 10, 2019 -- Daiichi Sankyo, Mitsubishi UFJ Capital, and the Tokyo Institute of Technology announced a three-year research collaboration focusing on creation of insulin-producing cells from iPS cells for use in regenerative medicine and cell therapy.
The Kume and Shiraki Lab at the School of Life Science and Technology at Tokyo Tech has developed a technique to produce pancreatic [beta] cells (insulin-secreting cells in the pancreas) derived from human iPS cells at a high rate.
It has been found that this technique enables creation of iPS cell-derived insulin producing cells similar to the body's own pancreatic [beta] cells in combination with Daiichi Sankyo technology.
The collaborators say the research will improve the performance and manufacturing process for such iPS cell-derived insulin producing cells, aiming at practical application as an innovative therapy for severe type 1 diabetes, for which blood glucose management is difficult with conventional insulin therapy, and in which high unmet medical needs exist.
To carry out the research, a new company called OiDE BetaRevive, Inc. (Chuo-ku, Tokyo) was established and will be wholly funded by the OiDE Fund Investment Limited Partnership operated by Mitsubishi UFJ Capital.
If the goals of the three-year joint research are achieved, Daiichi Sankyo will purchase all of the stock of BetaRevive to continue research for the project on its own.
After a successful product launch, Daiichi Sankyo will pay considerations to Tokyo Tech in royalties.
The research is the fourth OiDE Fund investment, and Daiichi Sankyo and Mitsubishi UFJ Capital plan to continue to carry out further open innovation projects to develop new drug discovery platform technologies using the OiDE fund.
Type 1 diabetes develops when insulin-producing [beta] cells in the pancreas are destroyed for some reason. Insulin formulations are used for its treatment.
However, good glycemic control cannot be achieved in some patients with markedly impaired endogenous insulin secretion.
Patients may experience repeated severe hypoglycemic attacks leading to worsening of QOL and prognosis.
Although islet transplantation is considered to be effective in those cases, a new therapy is desired due to the issue of shortage of donors.
Contact: Daiichi Sankyo Company, Limited (media) Tel: 03-6225-1126; (investor) Tel: 03-6225-1125
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Basic Research|
|Publication:||Stem Cell Lab World|
|Date:||Feb 18, 2019|
|Previous Article:||CNS Drug Candidate Stimulates New Brain Cells In Animal Studies.|
|Next Article:||Exosome Production Scale-Up Data Presented.|